Cure My Disease

Don't miss your cure!

 Log in / Sign up

Higher-Dose radiation plus immunotherapy tested against advanced lung cancer

NCT ID NCT05269485

Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing whether high-dose hypofractionated radiotherapy followed by immune checkpoint inhibitors is safe and effective for people with stage III non-small cell lung cancer that cannot be removed by surgery. The trial enrolls adults aged 18 to 70 with specific types of lung cancer and no driving gene mutations. Participants receive one of two radiation schedules, then one year of immunotherapy. The main goal is to measure side effects like lung inflammation and esophageal irritation, while also tracking survival and cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypofractionated radiotherapy followed by immune checkpoint inhibitors
What this could lead to
If it works, this approach could improve local control and survival for people with stage III lung cancer that cannot be removed by surgery.
What could go wrong
This is a small phase II trial, so results may not hold in larger studies. Higher radiation doses can cause lung inflammation, esophageal irritation, or blood cell problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

36 people

The number who actually took part.

Started

Mar 2022

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-70 years old; * Eastern Cooperative Oncology Group (ECOG) 0-1; * Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma; * Wild-type of driven genes; * Stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT); * Surgically unresectable or deny of surgery; * Signature of inform consent. Exclusion Criteria: * Younger than 18 years old or older than 70 years old; * ECOG\>1; * Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma; * Mutant type of driven genes; * Non-stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT; * Surgically resectable; * No signature of inform consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non small cell lung cancer Radiotherapy side effect

Contacts and locations

Locations

  • Anhui Provicial Hospital

    Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.